AU2018256601A1 - Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer - Google Patents

Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer Download PDF

Info

Publication number
AU2018256601A1
AU2018256601A1 AU2018256601A AU2018256601A AU2018256601A1 AU 2018256601 A1 AU2018256601 A1 AU 2018256601A1 AU 2018256601 A AU2018256601 A AU 2018256601A AU 2018256601 A AU2018256601 A AU 2018256601A AU 2018256601 A1 AU2018256601 A1 AU 2018256601A1
Authority
AU
Australia
Prior art keywords
combination
breast cancer
vegf antibody
chemotherapy
treating breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018256601A
Inventor
Gwendolyn Fyfe
See Chun Phan
Xian Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009316409A external-priority patent/AU2009316409A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU2018256601A priority Critical patent/AU2018256601A1/en
Publication of AU2018256601A1 publication Critical patent/AU2018256601A1/en
Abandoned legal-status Critical Current

Links

Abstract

OF THE DISCLSOURE This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, 5 preferably in combination with one or more additional anti-tumor therapeutic agents. 10728141_1 (GHMatters) P87074.AU.3
AU2018256601A 2008-11-22 2018-11-01 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer Abandoned AU2018256601A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018256601A AU2018256601A1 (en) 2008-11-22 2018-11-01 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US61/117,102 2008-11-22
US61/178,009 2009-05-13
US61/179,307 2009-05-18
AU2009316409A AU2009316409A1 (en) 2008-11-22 2009-11-20 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
AU2015203013A AU2015203013A1 (en) 2008-11-22 2015-06-05 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
AU2017200300A AU2017200300A1 (en) 2008-11-22 2017-01-17 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
AU2018256601A AU2018256601A1 (en) 2008-11-22 2018-11-01 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2017200300A Division AU2017200300A1 (en) 2008-11-22 2017-01-17 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer

Publications (1)

Publication Number Publication Date
AU2018256601A1 true AU2018256601A1 (en) 2018-11-22

Family

ID=53561535

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015203013A Abandoned AU2015203013A1 (en) 2008-11-22 2015-06-05 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
AU2017200300A Abandoned AU2017200300A1 (en) 2008-11-22 2017-01-17 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
AU2018256601A Abandoned AU2018256601A1 (en) 2008-11-22 2018-11-01 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2015203013A Abandoned AU2015203013A1 (en) 2008-11-22 2015-06-05 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
AU2017200300A Abandoned AU2017200300A1 (en) 2008-11-22 2017-01-17 Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer

Country Status (1)

Country Link
AU (3) AU2015203013A1 (en)

Also Published As

Publication number Publication date
AU2017200300A1 (en) 2017-02-02
AU2015203013A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
MX340724B (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer.
TNSN05300A1 (en) Treatment with anti-vegf antibodies
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EA201070636A1 (en) INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT
TW200806322A (en) Diagnostics and treatments for tumors
HK1109638A1 (en) Dr5 antibodies and uses thereof dr5
EP1784639A4 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
MX2010001757A (en) Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof.
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
EA201000644A1 (en) ANTIBODIES FOR THE TREATMENT AND PREVENTION OF THE ALZGEIMER'S DISEASE AND THEIR APPLICATION
UA106194C2 (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2010054377A3 (en) Fully human antibodies against n-cadherin
MX2009010269A (en) Methods of treating cancer by administering human il-18 combinations.
MX2018009499A (en) Egfl6 specific monoclonal antibodies and methods of their use.
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
MX336476B (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer.
ATE525401T1 (en) MHC CLASS I AND II PEPTIDE ANTIGENS DERIVED FROM TUMOR ANTIGEN 5T4
AU2018256601A1 (en) Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
WO2008118324A3 (en) Composition and method of treating cancer with an anti-uroplakin ib antibody
TW200640948A (en) DR5 antibodies and uses thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted